Scott A Barman1, Feng Chen1, Yunchao Su2, Christiana Dimitropoulou2, Yusi Wang2, John D Catravas2, Weihong Han2, Laszlo Orfi2, Csaba Szantai-Kis2, Gyorgy Keri2, Istvan Szabadkai2, Nektarios Barabutis2, Olga Rafikova2, Ruslan Rafikov2, Stephen M Black2, Danny Jonigk2, Athanassios Giannis2, Reto Asmis2, David W Stepp2, Ganesan Ramesh2, David J R Fulton1. 1. From the Department of Forensic Medicine, Nanjing Medical University, Jiangsu, China (F.C.); Department of Pharmacology and Toxicology (S.A.B., Y.S., W.H., D.J.R.F.) and Vascular Biology Center (F.C., C.D., Y.W., J.D.S., N.B., O.R., R.R., S.M.B., D.W.S., G.R., D.J.R.F.), Georgia Regents University, Augusta; Vichem Chemie, Ltd, Budapest, Hungary (L.O., C.S.-K., G.K., I.S.); Institute for Organic Chemistry, University of Leipzig, Leipzig, Germany (A.G.); Institute for Pathology, Hannover Medical School, Hannover, Germany (D.J.); Departments of Clinical Laboratories and Biochemistry, University of Texas Health Science Center at San Antonio (R.A.); and Pathobiochemical Research Group of Hungarian Academy of Sciences (G.K.) and Department of Pharmaceutical Chemistry (L.O.), Semmelweis University, Budapest, Hungary. sbarman@gru.edu dfulton@gru.edu fchen@gru.edu. 2. From the Department of Forensic Medicine, Nanjing Medical University, Jiangsu, China (F.C.); Department of Pharmacology and Toxicology (S.A.B., Y.S., W.H., D.J.R.F.) and Vascular Biology Center (F.C., C.D., Y.W., J.D.S., N.B., O.R., R.R., S.M.B., D.W.S., G.R., D.J.R.F.), Georgia Regents University, Augusta; Vichem Chemie, Ltd, Budapest, Hungary (L.O., C.S.-K., G.K., I.S.); Institute for Organic Chemistry, University of Leipzig, Leipzig, Germany (A.G.); Institute for Pathology, Hannover Medical School, Hannover, Germany (D.J.); Departments of Clinical Laboratories and Biochemistry, University of Texas Health Science Center at San Antonio (R.A.); and Pathobiochemical Research Group of Hungarian Academy of Sciences (G.K.) and Department of Pharmaceutical Chemistry (L.O.), Semmelweis University, Budapest, Hungary.
Abstract
OBJECTIVE: Pulmonary hypertension (PH) is a progressive disease arising from remodeling and narrowing of pulmonary arteries (PAs) resulting in high pulmonary blood pressure and ultimately right ventricular failure. Elevated production of reactive oxygen species by NADPH oxidase 4 (Nox4) is associated with increased pressure in PH. However, the cellular location of Nox4 and its contribution to aberrant vascular remodeling in PH remains poorly understood. Therefore, we sought to identify the vascular cells expressing Nox4 in PAs and determine the functional relevance of Nox4 in PH. APPROACH AND RESULTS: Elevated expression of Nox4 was detected in hypertensive PAs from 3 rat PH models and human PH using qualititative real-time reverse transcription polymerase chain reaction, Western blot, and immunofluorescence. In the vascular wall, Nox4 was detected in both endothelium and adventitia, and perivascular staining was prominently increased in hypertensive lung sections, colocalizing with cells expressing fibroblast and monocyte markers and matching the adventitial location of reactive oxygen species production. Small-molecule inhibitors of Nox4 reduced adventitial reactive oxygen species generation and vascular remodeling as well as ameliorating right ventricular hypertrophy and noninvasive indices of PA stiffness in monocrotaline-treated rats as determined by morphometric analysis and high-resolution digital ultrasound. Nox4 inhibitors improved PH in both prevention and reversal protocols and reduced the expression of fibroblast markers in isolated PAs. In fibroblasts, Nox4 overexpression stimulated migration and proliferation and was necessary for matrix gene expression. CONCLUSION: These findings indicate that Nox4 is prominently expressed in the adventitia and contributes to altered fibroblast behavior, hypertensive vascular remodeling, and development of PH.
OBJECTIVE:Pulmonary hypertension (PH) is a progressive disease arising from remodeling and narrowing of pulmonary arteries (PAs) resulting in high pulmonary blood pressure and ultimately right ventricular failure. Elevated production of reactive oxygen species by NADPH oxidase 4 (Nox4) is associated with increased pressure in PH. However, the cellular location of Nox4 and its contribution to aberrant vascular remodeling in PH remains poorly understood. Therefore, we sought to identify the vascular cells expressing Nox4 in PAs and determine the functional relevance of Nox4 in PH. APPROACH AND RESULTS: Elevated expression of Nox4 was detected in hypertensive PAs from 3 rat PH models and human PH using qualititative real-time reverse transcription polymerase chain reaction, Western blot, and immunofluorescence. In the vascular wall, Nox4 was detected in both endothelium and adventitia, and perivascular staining was prominently increased in hypertensive lung sections, colocalizing with cells expressing fibroblast and monocyte markers and matching the adventitial location of reactive oxygen species production. Small-molecule inhibitors of Nox4 reduced adventitial reactive oxygen species generation and vascular remodeling as well as ameliorating right ventricular hypertrophy and noninvasive indices of PA stiffness in monocrotaline-treated rats as determined by morphometric analysis and high-resolution digital ultrasound. Nox4 inhibitors improved PH in both prevention and reversal protocols and reduced the expression of fibroblast markers in isolated PAs. In fibroblasts, Nox4 overexpression stimulated migration and proliferation and was necessary for matrix gene expression. CONCLUSION: These findings indicate that Nox4 is prominently expressed in the adventitia and contributes to altered fibroblast behavior, hypertensive vascular remodeling, and development of PH.
Authors: Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-02-03 Impact factor: 5.464
Authors: Mark W Majesky; Xiu Rong Dong; Virginia Hoglund; William M Mahoney; Guenter Daum Journal: Arterioscler Thromb Vasc Biol Date: 2011-07 Impact factor: 8.311
Authors: Fares A Masri; Suzy A A Comhair; Iva Dostanic-Larson; Francisco Takao Kaneko; Raed A Dweik; Alejandro C Arroliga; Serpil C Erzurum Journal: Clin Transl Sci Date: 2008-09 Impact factor: 4.689
Authors: Charles E Norton; Brad R S Broughton; Nikki L Jernigan; Benjimen R Walker; Thomas C Resta Journal: Antioxid Redox Signal Date: 2012-10-18 Impact factor: 8.401
Authors: Rebecca Bowers; Carlyne Cool; Robert C Murphy; Rubin M Tuder; Matthew W Hopken; Sonia C Flores; Norbert F Voelkel Journal: Am J Respir Crit Care Med Date: 2003-12-30 Impact factor: 21.405
Authors: Evgeny A Zemskov; Qing Lu; Wojciech Ornatowski; Christina N Klinger; Ankit A Desai; Emin Maltepe; Jason X-J Yuan; Ting Wang; Jeffrey R Fineman; Stephen M Black Journal: Antioxid Redox Signal Date: 2019-03-19 Impact factor: 8.401
Authors: G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood Journal: Br J Pharmacol Date: 2016-07-14 Impact factor: 8.739
Authors: David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman Journal: Antioxid Redox Signal Date: 2019-03-29 Impact factor: 8.401
Authors: Feng Chen; Xueyi Li; Emily Aquadro; Stephen Haigh; Jiliang Zhou; David W Stepp; Neal L Weintraub; Scott A Barman; David J R Fulton Journal: Free Radic Biol Med Date: 2016-08-03 Impact factor: 7.376
Authors: Qian Xu; Amol A Kulkarni; Ayyiliath M Sajith; Dilbi Hussein; David Brown; Osman F Güner; M Damoder Reddy; E Blake Watkins; Bernard Lassègue; Kathy K Griendling; J Phillip Bowen Journal: Bioorg Med Chem Date: 2017-12-17 Impact factor: 3.641
Authors: Mark D Stevenson; Chandrika Canugovi; Aleksandr E Vendrov; Takayuki Hayami; Dawn E Bowles; Karl-Heinz Krause; Nageswara R Madamanchi; Marschall S Runge Journal: Antioxid Redox Signal Date: 2018-12-28 Impact factor: 8.401